Cempra (CEMP) : 10 analysts are covering Cempra (CEMP) and their average rating on the stock is 1.25, which is read as a Strong Buy. 8 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. Cempra (CEMP) also receives 1 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 1 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Cempra (CEMP) : The highest level Cempra (CEMP) is projected to reach is $51 for the short term and the lowest estimate is at $23. The consolidated price target from 9 rating analysts who initiate coverage on the stock is $39 and the possibility the share price can swing is $8.08.
Cempra, Inc. has dropped 0.57% in the last five trading days, however, the shares have posted positive gains of 26.94% in the last 4 weeks. Cempra, Inc. is up 35.13% in the last 3-month period. Year-to-Date the stock performance stands at -26.6%. Cempra (NASDAQ:CEMP): stock turned positive on Tuesday. Though the stock opened at $23.12, the bulls momentum made the stock top out at $23.24 level for the day. The stock recorded a low of $22.65 and closed the trading day at $22.85, in the green by 0.93%. The total traded volume for the day was 411,786. The stock had closed at $22.64 in the previous days trading.
Cempra Inc. is a clinical-stage pharmaceutical company focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Companys lead product, solithromycin, is being developed in oral capsules, intravenous, or IV, and suspension formulations, initially for the treatment of community acquired bacterial pneumonia, or CABP, an infection of the respiratory tract. The Companys second product is Taksta, an antibiotic known as fusidic acid, that has been used for decades outside the United States, including Western Europe, but , which has never been approved in the United States. The Company is developing Taksta in the United States as an oral treatment of refractory bone and joint infections caused by staphylococci.